BANB

The ticker submitted for analysis carries the label Banca Syz. The underlying instrument, BANB on the Swiss Exchange, is Bachem Holding AG, the Bubendorf-based peptide contract development and manufacturing organization. This analysis proceeds on the actual security identified by the ISIN CH1176493729 and by the fundamental data provided, which is unambiguously Bachem. Any crosswalk to a Geneva-based private bank is a labeling error upstream of this research note.

Bachem is one of the most peculiar structural stories in European healthcare supply chains. On paper it is a Swiss specialty chemicals company with CHF 695 million in 2025 revenue, a 21.6% EBIT margin, and a market capitalization near CHF 5.2 billion. In practice it is the second-largest independent producer of synthetic peptide active pharmaceutical ingredients in the world, and its revenue curve has become mathematically inseparable from the commercial trajectory of a single drug class: GLP-1 receptor agonists. The 2025 revenue acceleration, the Q4 2025 print of CHF 382 million that alone exceeded full-year 2021 revenue, and the analyst consensus projecting CHF 1.78 billion by 2030 are not the output of a diversified chemicals company. They are the fingerprint of a capacity-constrained supplier to an obesity drug supercycle.

The central analytical observation is this. Bachem does not own a product. It owns a position inside the regulatory dossiers of drugs it did not invent, for molecules it did not design, sold to patients it will never meet. The moat is real, but it is rented. Every gram of semaglutide-adjacent peptide that leaves Bubendorf or Sisslerfeld reaches a patient only because a customer chose Bachem over a rival, and kept that choice in its drug master file through the FDA's narrow tolerance for supplier substitution. This is what makes the company fascinating as a structural study: the economics of a Status-Quo-Player, layered onto the vulnerability of a Dependent. The question this analysis answers is whether capacity scarcity in regulated peptide manufacturing is durable enough to transform Bachem into something more than a contractor, or whether the peptide supercycle ends the way every supercycle has historically ended, with overcapacity chasing a normalized demand curve.